Overview: FDA Warning Letters and recent recalls in the media show major cGMP deficiencies in companies' validation activities.
A major problem area is lack of defined risk-based verification and validation comprehensive planning, defined and documented. Regulatory expectations now include a corporate and site Master Plan, which needs to incorporate product risk management, eg., ISO 14971:2007 (Devices) and ICH Q9 (Pharma). This webinar will address: Product, Process / Equipment, and QMS V&V; when DQs, IQs, OQs, and PQs are required; how does software validation for product, process or QMS / 21 CFR Part 11 differ. A suggested matrix is provided. Some viable models, accepted by the FDA, will be considered.
Areas Covered in the Session:
Verification or Validation - heightened regulatory expectations
The Master Validation Plan
Product, Process and Equipment Validation – differences
When and how to use DQ, IQ, OQ and PQs
Use the Risk Management File / Report for resource constraints